Osteoarthritis of Knee
Conditions
Keywords
Osteoarthritis, knee, hyaluronic, collagen, neoial, gonarthrosis
Brief summary
Osteoarthritis (OA) is one of the most frequent causes of pain and disability in adults. According to the Osteoarthritis Research Society International (OARSI), at least 40% of people over the age of 65 suffer from symptomatic osteoarthritis of the hip or knee. Knee osteoarthritis (OA) is the eleventh leading cause of years lived with disability according to the World Health Organization. The guidelines show that treatment with intra-articular injections of hyaluronic acid (HA) leads to a slow, prolonged pain relief (up to six months after the first injection); On the other hand, there is little evidence in the literature about the intra-articular use of isolated collagen or in combination with hyaluronic acid in the treatment of knee osteoarthritis. The present study showed a clinically good safety profile and provided preliminary evidence of the efficacy of NEOIAL HC for the treatment of symptomatic knee OA
Interventions
DEVICENeoial HC
Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
Sponsors
Nextrasearch S.r.l.s.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Of the 36 screened patients, 15 had to be included and treated patients (15 as planned per-protocol). Of these, 14 patients completed the study and attended the visit at Month 6 . Since all patients were treated , the Full Analysis Set (FAS, all randomized and treated patients) was identical to the Safety Set (all treated patients). The mean age at enrollment was 71±7 years (range 54-80;median 73), and 12 of patients were women (85.7%) and 2 male (14.3%) . The mean BMI were26.6±3.4 (range 21-30;median 28.5) . Overall patients had knee OA with a Kellgren-Lawrence grade II and III (50/50).
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Age * Knee OA * VAS \> 3 * Kellegren radiographic stage 3-4
Exclusion criteria
* presence of joint effusion, * VAS score \<3 according to the American College of Rheumatology Criteria * neoplasms, * haematological diseases, * specific rheumatological pathologies, * bleeding disorders, local infections, * refusal or non-compliance of the patient, * candidacy for knee joint replacement or any intra-articular injection during the previous year, * addiction to opioid drugs, * recent heart attack or stroke.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VAS score | 6 months | The primary objective in the study was to evaluate the mean changes from baseline at Month 3 in VAS Pain Subscale Score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Knee Injury and Osteoarthritis Outcome Score (KOOS) | 6 months | The KOOS is self-administered and assesses 5 domains: pain, symptoms, activities of daily living (ADL), sport and recreation function, and knee-related quality of life. This scale is used to evaluate knee function in terms of activities of daily living (ADL). |
| Lequesne | 6 months | measure the severity for osteoarthritis for the knee (ISK). This can be used to assess the effectiveness of therapeutic interventions |
| Western Ontario McMaster Universities (WOMAC®) VA3.1 | 6 months | self-administered, patient-centered health status questionnaires allowing a thorough evaluation of pain, stiffness, and knee function (24 questions through three subscales) |
Other
| Measure | Time frame | Description |
|---|---|---|
| occurrence of AEs and serious adverse events (SAEs) | through study completion, an average of 1 year | reported on patients' open questionnaires, related or not to the product or procedures, abnormal laboratory results in terms of hematology, serum chemistry, and coagulation parameters, and clinically relevant findings at physical examination (including vital signs) during the entire study duration |
Countries
Italy
Outcome results
None listed